In the last twelve months, Innate Pharma SA generated $143.2 million in revenue and $1.3 million in net income. The company has a market-cap of $560.3 million.
Citigroup, SVB Leerink and Evercore ISI acted as the underwriters for the IPO.
Innate Pharma SA provided the following description of their company for its IPO: “(Note: Not an IPO: Our ordinary shares are listed on Euronext Paris under the symbol “IPH.” On October 3, 2019, the last reported sale price of our ordinary shares on Euronext Paris was €6.85 per ordinary share, equivalent to a price of $7.50 per ADS, assuming an exchange rate of €1.00 = $1.0951, the exchange rate on October 3, 2019.) We are a biotechnology company focused on discovering, developing and commercializing first-in-class therapeutic antibodies designed to harness the immune system for the treatment of oncology indications with significant unmet medical need. We have extensive experience in research and development in immuno-oncology, having been pioneers in the understanding of natural killer cell, or NK cell, biology, and later expanding our expertise in the tumor microenvironment, tumor antigens and antibody engineering fields. “.
Innate Pharma SA was founded in 1999 and has 208 employees. The company is located at 117, Avenue de Luminy, 13009 Marseille, France and can be reached via phone at 33 4 30 30 30 30 or on the web at http://www.innate-pharma.com.
Receive News & Ratings for Innate Pharma SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma SA and related companies with MarketBeat.com's FREE daily email newsletter.